Testing dupilumab for itchy inherited genetic skin disorders
Treatments studied
Part of Genetic & congenital, Skin clinical trials.
This early trial tests whether dupilumab can reduce itching in people with certain inherited (genetic) inflammatory skin conditions. It may help by calming skin inflammation that causes ongoing itch and sleep problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re older than 6 months at the screening visit
- You have a diagnosed genetic skin disorder (ideally confirmed by genetics or a skin sample)
- You (or your family) can share your genetic test results, or provide a saliva/buccal swab/blood sample for testing
- Your itch has been bad recently: average itch score 4+ and worst itch score 5+ in the past 7 days
- You can wear a sensor and do weekly itch/sleep check-ins for the first 24 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether dupilumab can improve daily body clock (circadian function), sleep, and itching in children with moderate-to-severe eczema that isn’t well controlled by creams. It may help kids who are having significant sleep trouble and ongoing itch.
This trial tests a new medicine (Dupilumab) for children with a severe itchy skin condition called prurigo nodularis. It aims to see if the treatment is safe and how it works in the body.
This Phase 3 study tests whether dupilumab injections can reduce severe itching that has no clear cause. It also checks how safe the medicine is over the study period.
This study looks at how well dupilumab works for children and teens with severe eczema (atopic dermatitis) even when the rash is not widespread. It aims to see if the treatment helps with itching, quality of life, and rashes in visible or sensitive areas.
This trial tests if dupilumab (Dupixent) can help adults with long-lasting, severe itching from healed burn scars. It is for people whose itching has not improved with standard treatments like antihistamines.
This Phase 4 study looks at how dupilumab works in people with moderate-to-severe atopic dermatitis (eczema), and whether the mechanism differs across ethnic backgrounds. If you’re eligible, it may help doctors understand who benefits most from dupilumab.
Hear when a new Skin Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.